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Objectives: The clinical and cost-effectiveness of left ventricular assist devices as
destination therapy for people with end-stage heart failure is assessed through a
systematic review and economic evaluation.
Methods: Systematic review was performed of randomized controlled trials,
quasiexperimental studies, case series, and case studies identified through searching
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eighteen electronic databases, bibliographies, and consultation with experts and
manufacturers. Studies assessed survival, functional capacity, and quality of life.
Cost-effectiveness was assessed through a 5-year decision analytic model to estimate the
incremental cost-effectiveness ratio for using left ventricular assist devices compared with
usual care.
Results: Six studies met the inclusion criteria, showing that left ventricular assist devices
appear beneficial, improving survival and quality of life. Adverse events are a serious
concern. The economic evaluation showed that left ventricular assist devices had a cost
per quality adjusted life year of £170,616. Sensitivity analysis showed that the
cost-effectiveness was not sensitive to changes in costs or utility.
Conclusions: Although left ventricular assist devices appear clinically effective as
destination therapy, it is unlikely they will be cost-effective unless costs decrease or the
benefits of their use increase.
Keywords: Heart failure, Left ventricular assist devices, Systematic review, Economic
evaluation, Health technology assessment
For people with severe or end-stage heart failure (ESHF),
treatment options are limited. Heart transplantation has been
the only treatment that has provided substantial benefit,
improving the length and quality of life (3;18). Serious short-
ages in donor organs have restricted the use of heart trans-
plantation to a few (11;12;19). As a result, increasing at-
tention has focused on the role of mechanical circulatory
support, either as a replacement for the natural heart (total
artificial hearts) or as a support that works in parallel with
the heart (ventricular assist device). Left ventricular assist
devices (LVADs), originally developed to bridge people to
heart transplantation, have continued to evolve. Miniaturiza-
tion, low power use, and ease of implantation, allied with
decreasing costs and advances in patient care, have made
LVADs an acceptable treatment option (14). With the increas-
ing scarcity of donor organs for transplantation, people have
been supported for longer periods, extending to months or
even years. Inevitably, this finding has raised the possibility of
using LVADs as destination therapy, providing an alternative
through long-term chronic support for those awaiting heart
transplantation or those ineligible for transplantation. With
the fast changing nature of the technology and more than
twenty different devices having been developed, uncertainty
remains as to the suitability of these devices as destination
therapy. Before adopting new technologies, it is important
to evaluate the evidence of their benefits, risks, and costs.
This study summarizes the results of a systematic review
and economic evaluation commissioned by the Department
of Health’s Health Technology Assessment Programme to
assess the evidence of the clinical and cost-effectiveness of
all available LVADs used as destination therapy for people
with ESHF (2).
METHODS
We searched for published and unpublished studies using
eighteen electronic databases, including Medline, Cochrane
Library, and Embase, from their inception to December 2004
with no language restrictions (details of search strategy avail-
able elsewhere) (2). Also, we searched through bibliogra-
phies of related publications and contacted relevant experts
and manufacturers of LVADs to identify additional refer-
ences. Studies reported as abstracts or conference presenta-
tions were only considered for inclusion if adequate details
of their methodology and results were provided to judge the
quality and rigor of the study.
We included randomized controlled trials (RCTs), con-
trolled clinical trials, cohort studies, case series, and case
studies that evaluated currently available LVADs used as
destination therapy for people 16 years of age and older
with ESHF. Natural history studies were sought as it was
recognized that experimental studies of this rapidly evolving
technology may be scarce. These studies may provide useful
evidence of effectiveness where outcomes are poor and pre-
dictable without treatment (21). We placed an emphasis on
including studies that used the most rigorous study designs
and that included an appropriate comparator, whether another
LVAD or optimal medical management. We excluded studies
if LVADs were used during the perioperative period only or
as an emergency rescue strategy during an operation. Studies
were included if they assessed survival, functional capacity,
or quality of life as primary outcome measures. Standard
criteria were used to assess the quality of included studies
(1;20). Two reviewers independently applied inclusion crite-
ria, extracted data, and assessed quality. Any differences were
resolved through independent assessment by a third reviewer.
We extracted standard information on study characteristics,
methods, and results wherever possible to allow comparison
across different studies. Clinical effectiveness was assessed
through a narrative comparison of different outcomes. Differ-
ences in, or insufficient details on, study designs, outcomes
used, patient characteristics, or intervention used precluded
meta-analysis.
The economic evaluation developed for this study was
a cost utility analysis using a decision analytic model
based on a Markov approach. A detailed discussion of the
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methodology used to develop the evaluation is available else-
where (2). It compared the benefits and costs of the use of
LVADs with that of usual medical care as destination therapy
for people with ESHF through calculation of an incremental
cost-effectiveness ratio (ICER) (6). The evaluation adopted
an National Health Service and Personal Social Services per-
spective for costs and benefits for 2003 (UK prices). The base
case focused on devices that were considered to be the most
clinically effective in the systematic review. Benefits were as-
sessed in terms of changes in patient survival and quality of
life. The Randomized Evaluation of Mechanical Assistance
for the Treatment of Congestive Heart Failure (REMATCH)
study (15), which compared the HeartMate Vented Electric
(VE) LVAD with optimal medical management, provided the
only source of data measuring patient survival with an indi-
cation of time to an event through Kaplan–Meier survival
curves. Although these survival curves were censored at 30
months, we extended these through survival analysis until
all patients had died (60 months) to ensure all survival ben-
efits were accounted for in the model. No studies reporting
utility values for destination therapy were identified by the
systematic review. Instead, we obtained utility values using
a panel-based approach, mapping the Minnesota Living with
Heart Failure questionnaire to utilities using different scenar-
ios from data reported in the REMATCH study (2;15). Costs
reflected current clinical practice in the United Kingdom and
originate from the systematic review, expert clinical advice,
UK hospitals, and device manufacturers (Table 1) (2). Bene-
fits were discounted at 1.5 percent and costs at 6 percent. Re-
sults were presented as incremental cost per quality-adjusted
Table 1. Component Costs Used in the Economic Evaluation
Cost Event rate Total cost
Component (unit in £) per patient per patient (£)
LVAD costs
Pre-LVAD implant 2,202 1.3125 2,891
assessmentsa
Implant operationa 36,986 1 36,986
Follow-up outpatient 99 6 595
visita
Readmissionsa 5,391 3 16,174







LVAD ongoing Quarterly 4,192
management costsa
Medical managementa Quarterly 1,382
a Caine N, Papworth Hospital NHS Trust, unpublished data, 2004.
b MicroMed Technology, Inc., unpublished data, 2003.
c Jarvik Heart, Inc., unpublished data, 2003.
d U.S. costs converted to UK£ at $1.8316 = £1 (Wall Street Journal Europe,
9 January 2004).
LVAD, left ventricular assist device.
life-years (QALYs) gained (6). One-way and multiway sen-
sitivity analyses examining different devices, costs, utilities,
efficacy, and discounting were carried out.
RESULTS
Systematic Review of Clinical
Effectiveness
Six studies assessing the clinical effectiveness of LVADs as
destination therapy for ESHF met the inclusion criteria, with
studies of the HeartMate VE LVAD (15), LionHeart LVAD
(7), Novacor LVAD (4;5), Toyobo LVAD (16), and Jarvik
2000 LVAD (8;10;17;22;24). Only the RCT assessing the
HeartMate VE LVAD included a comparator (15), that of op-
timal medical management, with the remaining studies being
either case studies (4;5;7;9;16) or case series (8;10;17;22;24).
Quantity and Quality of Evidence
The methodological quality and the quality of reporting of
the case series and case studies were judged to be weak.
The five studies lacked rigorous study designs and alloca-
tion process, as well as providing limited information on
the selection of participants, blinding, and methods of data
collection (Table 2) (4;5;7;10;16;17;22;24). In contrast, the
RCT comparing the use of the HeartMate VE LVAD with
optimal medical management was judged to be moderate
in its methodological quality and quality of reporting (15).
Although it had a strong study design and appeared to use
appropriate methods of allocation, it lacked an adequate de-
scription of the actual methods of randomization. The RCT
was judged to be weak in its selection of a representative
patient group, a consequence of changes to the a priori se-
lection criteria to ensure adequate enrollment. The risk of
confounding was considered low as the study demonstrated
that there were no significant differences between groups.
Blinding of patients and treating surgeons to interventions
was impossible and, despite efforts to limit the effects of
observational bias through the use of independent blinded
observers to judge outcomes, was judged to be methodolog-
ically weak. The validity and reliability of data collection
tools was considered weak due to the limited discussion in
the trial report. Reporting of withdrawals and drop-outs was
thought to be methodologically strong, identifying numbers
of, and reasons for, withdrawal as well as undertaking an in-
tention to treat analysis. The external validity of the studies
was assessed through a comparison of the characteristics of
the different patient groups (2). Although limited informa-
tion was provided, studies tend to focus on male patients 60
years of age and older who had suffered ischemic or dilated
cardiomyopathy and were ineligible for heart transplantation.
Survival
Studies showed that people supported with an LVAD had
a survival benefit when compared with those on optimal
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Table 2. Methodological Quality and Quality of Reporting of Studies
Study design Design & Data Intention
Study & comparator allocation Selection Confounding Blinding collection Withdrawals to treat
HeartMate LVAD




El Banayosy Case reports Weak Weak Not Weak Weak Not Not
et al. (7) (No comparator) applicable applicable applicable
Novacor LVAD
Dohmen Case report Weak Weak Not Weak Weak Not Not
et al. (4;5) (No comparator) applicable applicable applicable
Toyobo LVAD
Seki et al. (16) Case report Weak Weak Not Weak Weak Not Not
(No comparator) applicable applicable applicable
Jarvik 2000 LVAD
Frazier et al. (9) Case report Weak Weak Not Weak Weak Not Not
(No comparator) applicable applicable applicable
Frazier et al. (10) Case series Weak Weak Not Weak Weak Not Not
(No comparator) applicable applicable applicable
Note. The different criteria were rated following the guidelines provided by Thomas and colleagues (20), with some adaptations. Where criteria are rated as
weak, moderate, or strong, it relates to the study’s methodological control of the criteria. As such, if a study is rated as strong, it indicates that there is a low
risk of bias for the particular criteria. Where a component is considered not to be relevant to a study design, it is referred to as not applicable.
LVAD, left ventricular assist device; RCT, randomized controlled trial.
medical management or to the natural history of ESHF
(Table 3). The REMATCH trial reported that the HeartMate
VE LVAD provided a statistically significant 48 percent re-
duction in the risk of death from any cause at 30 months
compared with optimal medical management (15). Actuarial
survival was significantly higher for people with the Heart-
Mate VE LVAD compared with optimal medical manage-
ment at 1 year (survival difference 27 percent) and 2 years
(survival difference 15 percent) follow-up. Survival bene-
fits from the HeartMate LVAD were evident for people 60
years of age and younger and those 60 to 69 years of age
at 1-year follow-up. Studies of other devices were limited
to case studies or case series with no comparator, provid-
ing only an indication of any additional benefit gained when
compared with the natural history of the ESHF. A series of
six case studies of the LionHeart LVAD showed all survived
implantation of the device and that 50 percent survived to
18 months postimplantation (7). Case studies of the Nova-
cor and Toyobo LVADs reported that a patient receiving a
Novacor LVAD survived for over 4 years before dying (4;5)
and a patient receiving a Toyobo LVAD was still alive after
6 months (16). A case series of seven patients who received
a Jarvik 2000 LVAD reported that five continued to undergo
support (8;10;17;22;24). Mean survival for the four patients
at the UK center was 502 days (range, 95 to 889 days) and
for the 3 patients at the German center was 93 days (range,
66 days to 145 days). A separate case report of the Jarvik
2000 LVAD reported survival of a patient until discharge 6
weeks after implantation (9).
Functional Status
Changes to functional status were assessed in the REMATCH
trial and a case series (15;23). The REMATCH trial showed
that significantly more patients surviving on the HeartMate
LVAD experienced improvement in their functional status on
the New York Heart Association (NYHA) functional classi-
fication (baseline 100 percent NYHA IV; 12 months 100
percent NYHA II) compared with those on optimal medical
management (baseline 100 percent NYHA IV; 12 months 64
percent NYHA IV) (15). Similar improvements on NYHA
functional classification were reported in a case series for
three patients with Jarvik 2000 LVAD (baseline 100 percent
NYHA IV; 4 weeks postimplantation 66 percent NYHA I,
33 percent NYHA II) (23).
Quality of Life
The REMATCH trial and a case series of the Jarvik 2000
LVAD provided the only evidence on changes in quality of
life following LVAD implantation (Table 4) (15;23). Patients
with the HeartMate LVAD reported a significantly better
quality of life at 12 months after device implantation on
the physical function and emotional role subscales of the
thirty-six item Medical Outcomes Study Short-Form Gen-
eral Health Survey and on the Beck Depression Inventory
when compared with patients on optimal medical manage-
ment (15). Similar improvements were shown on the Min-
nesota Living with Heart Failure questionnaire, although dif-
ferences were not statistically significant. A case series of
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Table 3. Summary of Evidence of the Effect of LVADs on Patient Survival
Study Outcomes LVAD Comparison p value
HeartMate LVAD
Rose et al. (15) Survival at 1 year (actuarial) 52% 25% =.002
Survival at 2 years (actuarial) 23% 8% =.09
Median survival 408 days 150 days
Death from any cause
(Kaplan–Meier analysis over
30 months)
RR, .52; 95% CI, .34–.78; p = .001
1-year survival in patients
60 years old and younger
74% (n = 13) 33% (n = 9) =.05
1-year survival inpatients 60 to
69 years old
47% (n = 29) 15% (n = 20) =.009
LionHeart LVAD
El Banayosy et al. (7) Operative mortality 100% survived implantation
(n = 6)
No comparator Not applicable
Survival at 18 months
postimplantation
50% survived (n = 6). 3 patients
died at 17, 31, and 112 days
No comparator Not applicable
Novacor LVAD
Dohmen et al. (4;5) Survival Patient survived 1,514 days and
died of causes unrelated to the
pump
No comparator Not applicable
Toyobo LVAD
Seki et al. (16) Survival Patient died 190 days after
surgery
No comparator Not applicable
Jarvik 2000 LVAD
Frazier et al. (9) Survival postimplantation Patient survived for 6 weeks until
discharged
No comparator Not applicable
Westaby et al. (23) and
Frazier et al. (10)
Survival UK study (n = 4): 3 patients left
hospital within 4 weeks (one
report states that 3 patients left
hospital within 3–8 weeks), 2
patients died at 95 days and
382 days; the surviving 2
patients were still supported
after 642 and 889 days.
German study (n = 3): 3
patients surviving at follow-up
No comparator Not applicable
LVAD, left ventricular assist device; RR, relative risk; CI, confidence interval.
Table 4. Summary of Evidence of Quality of Life of Patients
Outcomes Intervention Comparison p value
Rose et al. (15)
Quality of life/function at 12 months
Physical function No. assessed: 23/24 (96%)
Score: 46 (SD 19)
No. assessed: 6/11 (55%)
Score: 21 (SD 21)
=.01
Emotional role No. assessed: 23/24 (96%)
Score: 64 (SD 45)
No. assessed: 6/11 (55%)




No. assessed: 23/24 (96%)
Score: 41 (SD 22)
No. assessed: 6/11 (55%)
Score: 58 (SD 21)
=.11
Beck Depression Inventory No. assessed: 22/24 (92%)
Score: 8 (SD 7)
No. assessed: 5/11 (45%)
Score: 13 (SD 7)
=.04
Westaby et al. (23)
Minnesota Living with
Heart Failure score
UK study (n = 4)
Patient 1: Pre-LVAD 89, Post-LVAD 24
Patient 2: Pre-LVAD 76, Post-LVAD died
Patient 3: Pre-LVAD 83, Post-LVAD 38
Patient 4: Pre-LVAD 87, Post-LVAD 45
Not applicable Not applicable
German study (n = 3)
Pre-LVAD 75.2 (SD 11.4), Postimplant
(2 months) 30.0 (SD 18.6)
Not applicable Not applicable
LVAD, left ventricular assist device.
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seven patients with the Jarvik 2000 LVAD showed that qual-
ity of life of the surviving patients improved following im-
plantation of the device (23).
Adverse Events
Serious adverse events were common among people with
ESHF who received either an LVAD or optimal medical ther-
apy. People receiving a HeartMate LVAD were twice as likely
to suffer a serious adverse event as those on optimal medical
management (rate ratio [RR], 2.35; 95 percent confidence
interval [CI], 1.86–2.95), with significantly higher rates of
non-neurological bleeding (RR, 9.47; 95 percent CI, 2.30–
38.90) and neurologic dysfunction (RR, 4.35; 95 percent CI,
1.31–14.50) (15). Also those with a HeartMate LVAD had
higher rates of supraventricular arrhythmias (RR, 3.92; 95
percent CI, .47–32.40), sepsis (RR, 2.03; 95 percent CI, .99–
4.13), local infection (RR, 1.63; 95 percent CI, .72–3.70),
renal failure (RR, 1.42; 95 percent CI, .54–3.71), miscella-
neous adverse events (RR, 1.41; 95 percent CI, .93–2.12),
syncope (RR, 1.31; 95 percent CI, .12–14.40), and serious
psychiatric disease (RR, 1.31; 95 percent CI, .12–14.30) than
patients receiving optimal medical management. In contrast,
people receiving optimal medical management had higher
rates of ventricular arrhythmias (RR, .45; 95 percent CI, .22–
.90), cardiac arrest (RR, .65; 95 percent CI, .21–2.00), and
nonperioperative myocardial infarction (RR, .65; 95 percent
CI, .04–10.30). Of the patients who died while supported
by a HeartMate LVAD, 41 percent were due to sepsis, 17
percent to LVAD failure, and 10 percent to cerebrovascu-
lar disease. Some 93 percent of the deaths among optimal
medical management patients were due to left ventricular
dysfunction. A series of six case reports of the LionHeart
LVAD showed that patients suffered from temporary hemol-
ysis (50 percent), bleeding (50 percent), early arrhythmia
(40 percent), and other adverse events (7). It was reported
that none of the patients with the LionHeart LVAD were re-
admitted with infection, thromboembolic complications, or
arrhythmias. Case studies of the Novacor (4;5) and Toyobo
(16) LVADs reported that a patient with the Novacor device
suffered from transient renal failure, bronchopneumonia, and
febrile episodes due to device-related infection, whereas a pa-
tient with a Toyobo LVAD suffered from multiple cerebral
embolisms and thrombi within the pump. The case series
of seven patients with Jarvik 2000 LVADs reported a case
of dyspnea, ventricular tachycardia, power supply problems,
and infection (8;10;17;22;24). No other device-related mal-
functions or infections were reported.
Cost-Effectiveness of LVADs as
Destination Therapy for ESHF
With no relevant cost-effectiveness studies available (2),
we developed an economic evaluation to assess the cost-
effectiveness of LVADs as destination therapy within the UK
setting. A base case comparison of the use of the Heart-
Mate LVAD with optimal medical management showed that
the LVAD offered an additional .6 quality-adjusted life-years
(QALYs) per patient over the 5-year duration of the model
at an additional cost of £102,000, producing an incremental
cost per QALY of £170,616 (Table 5).
One-way sensitivity analysis has shown that the model
was not sensitive to changes in costs, discount rates, or
changes in utility (Table 5). Only when survival improves
by 60 percent and device costs are reduced by 60 percent
compared with the base case scenario does the incremen-
tal cost-effectiveness ratio approach the generally accepted
cost-effectiveness thresholds for the United Kingdom (cost
per QALY, £30,000) (13).
DISCUSSION
The systematic review has revealed the lack of good qual-
ity evidence assessing the clinical effectiveness of LVADs
as destination therapy for people with ESHF. Despite these
limitations, it appears that LVADs are beneficial when com-
pared with optimal medical management or to the natural
history of ESHF, improving the length and quality of life
of patients. However, it is evident that adverse events were
associated with their use, including device malfunctions, in-
fections, and bleeding. When comparing the various devices,
the evidence was less clear due to the scarcity and poor
quality of the studies available, as well as the lack of di-
rect comparisons. Only the REMATCH trial comparing the
HeartMate VE LVAD with optimal medical management had
sufficient rigor to judge efficacy, showing benefit for patients
with an LVAD on measures of survival, functional status, and
quality of life. Studies of the Novacor, LionHeart, Toyobo,
and Jarvik 2000 were of poor methodological quality with no
comparator, limiting any comparison. Further investigations
are needed to adequately compare the different devices, tak-
ing into account the developments in devices, implantation
techniques, and patient care.
Limited evidence on the cost-effectiveness of LVADs
as destination therapy necessitated the development of a de
novo economic evaluation for the United Kingdom (2). The
analysis showed that LVADs are not a cost-effective option
with a cost per QALY of £170,616, which lies outside the
threshold for acceptability in the United Kingdom of £30,000
per QALY (13). One-way sensitivity analysis showed that
cost-effectiveness was not sensitive to changes in the costs
associated with care, discount rates, or measures of utility.
In fact, multiway sensitivity analysis showed that there
would need to be reductions of over 60 percent in the cost of
the devices as well as substantial improvements of over 60
percent in the length and quality of life of the patient for cost-
effectiveness to reach a cost per QALY of £30,000. Although
it is likely that the cost of devices will decline as the technol-
ogy develops and diffuses, doubts remain as to the extent to
which additional benefits can be achieved. Some of the un-
certainty reflects limitations in the evidence on benefits and
costs available, particularly for the new axial flow devices.
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Table 5. Baseline Results and Sensitivity Analyses
Baseline results
LVAD Optimal medical management Increment
Costs per patient per 3 months
Initial 3 months (£) 87,877 1,382 86,495
Each subsequent 3 months (6–63 months) (£) 4,192 1,382 2,811
Utility per patient .93 .70 .23
Cohort (100 patients)
Total cost, undiscounted (£) 11,033,131 562,991 10,470,141
Total QALYs, undiscounted 114.60 50.07 64.53
Total cost, discounted (£) 10,675,641 475,807 10,199,835
Total QALYs, discounted 104.19 44.41 59.78
Incremental cost-effectiveness ratio £170,616
One-way and multiway sensitivity analyses
Parameter varied Base case Range of values tested Cost per QALY (£) (range)
Baseline — — — 170,616
Upper and lower estimates of costs — −20% +20% 136,597 190,283
LVAD operation cost (£) 36,986 29,589 44,383 158,242 182,989
LVAD management cost (£) 16,769 13,415 20,123 164,300 176,932
Medical management cost (£) 5,526 4,421 16,769 154,423 172,207
HeartMate/Novacor LVADs cost (£) 48,000 38,400 57,600 154,557 186,674
MicroMed DeBakey LVAD cost (£) 48,000 28,000 42,000 137,161 160,579
Jarvik 2000 LVAD cost (£) 48,000 32,758 49,137 145,120 172,518
Improvement over REMATCH survival Not applicable 60% 40% 49,120 61,154
Improvement over REMATCH survival/
MicroMed DeBakey VAD device cost Not applicable +60%/−60% +40%/−40% 44,339 54,692
Costs discount rate 6% 3% 9% 169,638 171,656
Benefits discount rate 1.5% 0% 6% 167,059 181,491
Mean expert-based utilities
• Baseline (pretrial) .55 .45
• On LVAD support .925 .84 178,426
• On drug therapy .7 .57
LVAD, Left ventricular assist device; QALY, quality-adjusted life-years; REMATCH, Randomized Evaluation of Mechanical Assistance for the Treatment
of Congestive Heart Failure.
Consistent methods for undertaking systematic reviews
and economic evaluations were applied, with support
throughout the process from an expert advisory group of
clinicians, academics, and health professionals from the
United States and United Kingdom. Contact was made
with manufacturers, the major specialist centers implanting
LVADs in the United Kingdom, and authors of studies to try
and obtain additional information, with varying success. The
economic evaluation used the most up to date data available,
with evidence from our systematic review of clinical effec-
tiveness, patient utility data from on-going primary research
using a panel-based approach, and cost data from specialist
centers in the United Kingdom and device manufacturers.
Although the evaluation included different types of de-
vices, the evidence on benefits and costs tended to focus on
the more established displacement pulsatile devices, partic-
ularly the HeartMate LVAD. With the emergence of the new
axial flow devices and their increasing use in clinical prac-
tice, it is inevitable that the evidence base will continue to
improve. It will be important to incorporate any emerging ev-
idence into our systematic review and economic evaluation
to ensure it accurately assesses their benefits, risks, and costs.
Several areas for research have emerged, including the
epidemiology of ESHF to assess incidence, prevalence, and
characteristics of sufferers; long-term (at least 5 years follow-
up) RCTs focusing on head to head comparisons of different
devices and optimal medical management that encompass
a broad range of patient groups and assess patient survival,
functional ability, quality of life, and adverse events; and eco-
nomic evaluations as part of clinical trials with prospective
collection of data on quality of life, utilities, resources, and
costs.
POLICY IMPLICATIONS
New developments in LVADs and the management of pa-
tients have brought optimism concerning the permanent use
of LVADs for people with ESHF. The lack of alternative
treatment options has increased attention on the possibility
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of developing a specialist service within the United King-
dom. Despite the limited evidence assessing the effectiveness
of LVADs as destination therapy, our study has shown that
LVADs appear to be clinically effective, improving survival
and quality of life. However, currently they are not a cost-
effective option. As a consequence, it is unlikely that funding
of a service within the UK National Health Service would be
justified at present. Despite this outlook, it will be important
to continue to fund further good quality comparative research
to assess the benefits, risks, and costs of this rapidly develop-
ing technology. This research should be undertaken as part
of a nationally coordinated and funded formal research pro-
gram allowing the research objectives to be progressed while
maintaining the skills and structure of the current service.
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